CRIZANLIZUMAB CONTAINING ANTIBODY FORMULATION
The present invention relates to novel pharmaceutical formulations of an antibody against human P-selectin, especially SEG101, or an antibody having at most 3 amino acid difference from crizanlizumab, and processes for the preparation thereof and uses of the formulations. La présente invention conce...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | JELENKO, Aljosa HILBERT, Caroline GRIAUD, Francois CHELIUS, Dirk KROENER, Frieder ANKO, Maja PAUL, Rajsekhar BOADO, Lina BICKEL, Fabian SIGG, Juergen |
| description | The present invention relates to novel pharmaceutical formulations of an antibody against human P-selectin, especially SEG101, or an antibody having at most 3 amino acid difference from crizanlizumab, and processes for the preparation thereof and uses of the formulations.
La présente invention concerne de nouvelles formulations pharmaceutiques d'un anticorps contre la P-sélectine humaine, en particulier SEG101, ou un anticorps ayant au plus 3 acides aminés différents du crizanlizumab, et des procédés pour leur préparation et des utilisations des formulations. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2021087050A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2021087050A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2021087050A13</originalsourceid><addsrcrecordid>eNrjZNB1DvKMcvTz8YwK9XV0UnD29wtx9PTz9HNXcPQL8XTyd4lUcPMP8g31cQzx9PfjYWBNS8wpTuWF0twMym6uIc4euqkF-fGpxQWJyal5qSXx4f5GBkaGBhbmBqYGjobGxKkCAITeJsU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>CRIZANLIZUMAB CONTAINING ANTIBODY FORMULATION</title><source>esp@cenet</source><creator>JELENKO, Aljosa ; HILBERT, Caroline ; GRIAUD, Francois ; CHELIUS, Dirk ; KROENER, Frieder ; ANKO, Maja ; PAUL, Rajsekhar ; BOADO, Lina ; BICKEL, Fabian ; SIGG, Juergen</creator><creatorcontrib>JELENKO, Aljosa ; HILBERT, Caroline ; GRIAUD, Francois ; CHELIUS, Dirk ; KROENER, Frieder ; ANKO, Maja ; PAUL, Rajsekhar ; BOADO, Lina ; BICKEL, Fabian ; SIGG, Juergen</creatorcontrib><description>The present invention relates to novel pharmaceutical formulations of an antibody against human P-selectin, especially SEG101, or an antibody having at most 3 amino acid difference from crizanlizumab, and processes for the preparation thereof and uses of the formulations.
La présente invention concerne de nouvelles formulations pharmaceutiques d'un anticorps contre la P-sélectine humaine, en particulier SEG101, ou un anticorps ayant au plus 3 acides aminés différents du crizanlizumab, et des procédés pour leur préparation et des utilisations des formulations.</description><language>eng ; fre</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2021</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210506&DB=EPODOC&CC=WO&NR=2021087050A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76289</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210506&DB=EPODOC&CC=WO&NR=2021087050A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>JELENKO, Aljosa</creatorcontrib><creatorcontrib>HILBERT, Caroline</creatorcontrib><creatorcontrib>GRIAUD, Francois</creatorcontrib><creatorcontrib>CHELIUS, Dirk</creatorcontrib><creatorcontrib>KROENER, Frieder</creatorcontrib><creatorcontrib>ANKO, Maja</creatorcontrib><creatorcontrib>PAUL, Rajsekhar</creatorcontrib><creatorcontrib>BOADO, Lina</creatorcontrib><creatorcontrib>BICKEL, Fabian</creatorcontrib><creatorcontrib>SIGG, Juergen</creatorcontrib><title>CRIZANLIZUMAB CONTAINING ANTIBODY FORMULATION</title><description>The present invention relates to novel pharmaceutical formulations of an antibody against human P-selectin, especially SEG101, or an antibody having at most 3 amino acid difference from crizanlizumab, and processes for the preparation thereof and uses of the formulations.
La présente invention concerne de nouvelles formulations pharmaceutiques d'un anticorps contre la P-sélectine humaine, en particulier SEG101, ou un anticorps ayant au plus 3 acides aminés différents du crizanlizumab, et des procédés pour leur préparation et des utilisations des formulations.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2021</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZNB1DvKMcvTz8YwK9XV0UnD29wtx9PTz9HNXcPQL8XTyd4lUcPMP8g31cQzx9PfjYWBNS8wpTuWF0twMym6uIc4euqkF-fGpxQWJyal5qSXx4f5GBkaGBhbmBqYGjobGxKkCAITeJsU</recordid><startdate>20210506</startdate><enddate>20210506</enddate><creator>JELENKO, Aljosa</creator><creator>HILBERT, Caroline</creator><creator>GRIAUD, Francois</creator><creator>CHELIUS, Dirk</creator><creator>KROENER, Frieder</creator><creator>ANKO, Maja</creator><creator>PAUL, Rajsekhar</creator><creator>BOADO, Lina</creator><creator>BICKEL, Fabian</creator><creator>SIGG, Juergen</creator><scope>EVB</scope></search><sort><creationdate>20210506</creationdate><title>CRIZANLIZUMAB CONTAINING ANTIBODY FORMULATION</title><author>JELENKO, Aljosa ; HILBERT, Caroline ; GRIAUD, Francois ; CHELIUS, Dirk ; KROENER, Frieder ; ANKO, Maja ; PAUL, Rajsekhar ; BOADO, Lina ; BICKEL, Fabian ; SIGG, Juergen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2021087050A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2021</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>JELENKO, Aljosa</creatorcontrib><creatorcontrib>HILBERT, Caroline</creatorcontrib><creatorcontrib>GRIAUD, Francois</creatorcontrib><creatorcontrib>CHELIUS, Dirk</creatorcontrib><creatorcontrib>KROENER, Frieder</creatorcontrib><creatorcontrib>ANKO, Maja</creatorcontrib><creatorcontrib>PAUL, Rajsekhar</creatorcontrib><creatorcontrib>BOADO, Lina</creatorcontrib><creatorcontrib>BICKEL, Fabian</creatorcontrib><creatorcontrib>SIGG, Juergen</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>JELENKO, Aljosa</au><au>HILBERT, Caroline</au><au>GRIAUD, Francois</au><au>CHELIUS, Dirk</au><au>KROENER, Frieder</au><au>ANKO, Maja</au><au>PAUL, Rajsekhar</au><au>BOADO, Lina</au><au>BICKEL, Fabian</au><au>SIGG, Juergen</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>CRIZANLIZUMAB CONTAINING ANTIBODY FORMULATION</title><date>2021-05-06</date><risdate>2021</risdate><abstract>The present invention relates to novel pharmaceutical formulations of an antibody against human P-selectin, especially SEG101, or an antibody having at most 3 amino acid difference from crizanlizumab, and processes for the preparation thereof and uses of the formulations.
La présente invention concerne de nouvelles formulations pharmaceutiques d'un anticorps contre la P-sélectine humaine, en particulier SEG101, ou un anticorps ayant au plus 3 acides aminés différents du crizanlizumab, et des procédés pour leur préparation et des utilisations des formulations.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_WO2021087050A1 |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | CRIZANLIZUMAB CONTAINING ANTIBODY FORMULATION |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T17%3A55%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=JELENKO,%20Aljosa&rft.date=2021-05-06&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2021087050A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |